Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2004-12-21
2009-12-08
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C558S071000, C558S146000
Reexamination Certificate
active
07629333
ABSTRACT:
The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.
REFERENCES:
patent: 3892824 (1975-07-01), Piper et al.
patent: 4424216 (1984-01-01), Cerami et al.
patent: 5424471 (1995-06-01), Kennedy et al.
patent: 5488042 (1996-01-01), Grdina
patent: 5591731 (1997-01-01), Kennedy et al.
patent: 6384259 (2002-05-01), Stogniew et al.
patent: 6407278 (2002-06-01), Stogniew et al.
patent: 54-46722 (1979-04-01), None
patent: WO 89/05637 (1989-06-01), None
patent: WO 95/07700 (1995-03-01), None
patent: WO 97/11666 (1997-04-01), None
patent: WO98/34622 (1998-08-01), None
Bohuslavizki et al., “Protection of salivary glands by amifostine in patients treated with high dose radioiodine”, Eu. Jour. Cancer 33: S17 (1997).
Fitchner et al., “Effects of amifostine on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas”, Anti-cancer Drugs 8(2): 174-181 (1997).
Foster-Nora et al., “Amifostine for protection from antineoplastic drug toxicity”, Am. Jour. Health-system Pharm. 54(7): 787-800 (1997).
Jahansouz, H. et al. “Stability of ethiofos (NSC-29691) in aqueous solution and solid phase formulation”Pharm. Res. (NY) 7(9):S195 (1990) .
Kemp et al., “Amifostine pretreatment for protection against cyclophosphatide-induced and cisplastin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer”, Jour. Clin. Oncology 14(7): 2101-2112 (1996) .
Lewis, “A review of the use of chemoprotectants in cancer chemotherapy”, Drug Safety: An International Journal of Medical Toxicology and Drug Experience 11(3): 153-162 (1994) .
Spencer et al., “Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector”, Drugs 50(6): 1001-1031 (1995) .
Zadeii et al., “Stability of Ethiofos (NSC-29691) in aqueous solution and solid phase formulation”Pharm. Res. (NY) 8(10 Suppl.):S174 (1991) .
Stogniew Martin
Zadei Javad M.
Jones Day
MedImmune LLC
Truong Tamthom N
Wilson James O
LandOfFree
Stable amorphous amifostine compositions and methods for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable amorphous amifostine compositions and methods for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable amorphous amifostine compositions and methods for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090030